RocheRoche announced that it has signed a definite agreement under which Roche will acquire 100 per cent of Innovatis, a privately held company based in Bielefeld, Germany. Innovatis is a leading provider of automated cell analysis solutions, especially focusing on cell counting, viability testing, and cell function analysis in research, as well as bio-production. The purchase price for this transaction is 15 million Euros.

"This acquisition is a further step in our strategy to strengthen our position as a complete solution provider in the cell analysis research market," said Dr. Jürgen Schwiezer, CEO Division Roche Diagnostics. "Innovatis' technology will complement the existing Roche cell analysis portfolio and is synergistic to the xCELLigence technology launched in 2008."

Michael Grohmann, managing director of the Innovatis AG stated: "Roche has been one of our key customers for many years, in particular since the successful development of our cell analysis technology over 10 years ago. The Innovatis technology is very well placed for future growth as part of Roche Applied Science."

Innovatis will become a fully-integrated part of Roche Applied Science, a global business area of the diagnostic division of Roche. The company will continue to develop and market products for cell analysis through Roche Applied Science's extensive worldwide network. The transaction is expected to be completed within the next few weeks, subject to shareholder approval and regulatory clearance.